PCOS and Belly Fat: How Body Shape, Hormones, and Metabolism Connect

Loose gray shapes enter a clear prism and become three blue light bands.

Can carrying more fat around your abdomen be a sign of polycystic ovary syndrome, or PCOS? PCOS can be associated with greater fat accumulation around the waist, but body shape alone cannot tell you whether you have it. Diagnosis takes account of menstrual patterns, signs of excess androgens, and, when needed, the appearance of the ovaries on ultrasound. Other conditions and life stages can also change fat distribution.

What people mean by “PCOS belly”

“PCOS belly” is a social-media term for an abdominal pattern of fat distribution seen in many people with polycystic ovary syndrome. The phrase spread through TikTok and Instagram’s wellness community, often leaving the impression that this body shape points directly to PCOS.

Body shape cannot establish that. PCOS is estimated to affect 6% to 13% of people of reproductive age and often goes undiagnosed. The 2023 international guideline discusses this. Diagnosis uses the Rotterdam criteria, an international clinical standard. Source 1

Abdominal fat accumulation may be associated with the biological processes involved in PCOS. But “PCOS belly” describes an appearance, not a reliable basis for self-diagnosis.

How PCOS is diagnosed

In adults, the international diagnostic algorithm requires two of three features after other causes have been excluded: ovulatory dysfunction, clinical or biochemical androgen excess, and polycystic ovarian morphology. Under the 2023 guideline, adults can have ovarian morphology assessed by ultrasound or, alternatively, AMH within the diagnostic algorithm. AMH alone does not diagnose PCOS. When irregular cycles and hyperandrogenism are already present, neither ultrasound nor AMH is needed for this purpose. Adolescents must have both ovulatory dysfunction and hyperandrogenism; ultrasound and AMH are not recommended for diagnosis because they lack specificity in this age group. History and targeted assessment remain essential. Source 1

There are biological reasons why many people with PCOS accumulate fat around the abdomen. Visceral fat surrounds internal organs, and its amount is associated with both insulin resistance and androgen excess in people with PCOS. Fat outside the usual storage depots, known as ectopic fat, has also been described as a feature of metabolic dysfunction in PCOS. These associations still do not make body shape a diagnostic criterion: it can neither confirm nor exclude PCOS.

The hormonal and metabolic background to abdominal fat in PCOS

Several hormonal and metabolic processes interact in PCOS. Androgen excess and insulin resistance may favor central fat accumulation. Researchers also discuss the hypothalamic-pituitary-adrenal, or HPA, axis as a possible influence. It helps regulate cortisol, but its role in this particular fat-distribution pattern is not established here.

An evolutionary model of metabolic adaptation explores why this pattern recurs across different PCOS presentations. Interactions between androgens and diet are another area of research. In a nonhuman-primate study, elevated androgen levels and a diet that promoted weight gain amplified each other’s effects on biological processes in visceral fat. Animal findings cannot simply be transferred to humans. Source 1 Source 2

Androgen excess and visceral fat

Excess androgens are known as hyperandrogenism. This can involve increased free testosterone and often increased DHEA-S. Hyperandrogenism is one of the three diagnostic domains in the Rotterdam criteria.

Androgens have been described as an influence on preferential storage of fat in visceral and abdominal areas. In people with PCOS, visceral-fat thickness is associated with hyperandrogenism and cardiometabolic risk markers. That association alone does not establish which direction the effects run. Source 1

In primate models, androgen excess changes gene transcription and DNA methylation in visceral fat. These processes influence how genetic information is used. A study of fat-cell dysfunction in an animal model of PCOS also found differences according to tissue location. Central fat depots may therefore differ from other depots in their biological properties as well as their size. How far these findings apply to humans remains uncertain. Source 1 Source 2

Insulin resistance and central fat accumulation

Insulin resistance means that the body’s cells respond less readily to insulin. It is common in PCOS and can occur independently of body mass index, or BMI. Insulin resistance promotes additional androgen production in the ovaries, so metabolic dysfunction and hormone excess can reinforce one another.

This interaction is also relevant to cardiovascular risk. Epidemiological research describes an association between obesity and PCOS, with the potential for influences in both directions. Source 1 Source 2

Insulin resistance is also associated with ectopic fat stores. One study used magnetic resonance imaging to examine fat in the pancreas and liver and its relationship to impaired glucose regulation in PCOS. Such an association does not prove that organ fat causes the impairment or that routine MRI is necessary. Fasting insulin, HOMA-IR, and HbA1c do not measure this organ fat. The international guideline does not recommend available insulin assays for routine care; the 75-g oral glucose tolerance test is more accurate for assessing glucose metabolism than fasting glucose or HbA1c. Source 1 Source 2

The HPA axis, oxidative stress, and inflammation

Altered cortisol regulation, oxidative stress, and advanced glycation end products, or AGEs, have been discussed as further influences in PCOS. Oxidative stress has been implicated in its biology, and AGE accumulation may amplify metabolic disturbances. Inadequate vitamin D status, often described in PCOS, has also been studied in relation to obesity and insulin resistance. Separate papers address oxidative stress, AGEs, and vitamin D. These lines of research establish neither a diagnosis based on belly shape nor a general supplement program. Source 1 Source 2 Source 3

The role of cortisol regulation, in particular, remains uncertain. Wellness posts draw on parts of this discussion under the label “adrenal fatigue.” That broad explanation does not follow from the mechanisms being investigated.

Other possible explanations for abdominal fat

Central fat accumulation has several possible causes. Other symptoms, medical history, and appropriately selected tests help clinicians distinguish among them.

In Cushing syndrome, excess cortisol can lead to pronounced central fat accumulation. Clues can include purple stretch marks, noticeable facial redness, easy bruising, and weakness in the muscles close to the trunk. Biochemical evaluation may involve 24-hour urinary free cortisol, late-night salivary cortisol, or a low-dose dexamethasone suppression test. These tests address a different question from androgen measurements when PCOS is suspected.

An underactive thyroid slows metabolism and can cause weight changes resembling the metabolic changes of PCOS. TSH is an important laboratory marker in this differential assessment. An elevated result can prompt further thyroid evaluation, but it does not establish a specific cause by itself or exclude coexisting PCOS. Because the symptoms overlap, TSH testing in the initial assessment is discussed in connection with the 2023 international PCOS guideline. Source 1

Nonclassic congenital adrenal hyperplasia, or NCAH, is a later-presenting form of an inherited adrenal disorder. It can cause irregular cycles and hirsutism, increased hair growth in an androgen-dependent pattern. Medical history alone may not distinguish it from PCOS. A morning follicular-phase 17-hydroxyprogesterone measurement helps with this assessment. A result above 2 ng/mL is sometimes cited as a threshold for an ACTH stimulation test, but it is not a universal decision limit without clinical context and the laboratory method. The Endocrine Society recommends an early-morning measurement, preferably by LC-MS/MS, and further stimulation testing for borderline results. The historical range of 200–400 ng/dL, equivalent to 2–4 ng/mL, depends on the assay. Source 1

Insulin resistance and metabolic syndrome can occur with visceral fat accumulation without PCOS. Menstrual history, androgen measurements, and, when needed, pelvic ultrasound help establish whether the Rotterdam criteria are met or whether metabolic syndrome is present without the corresponding hormonal features.

During perimenopause, fat may accumulate more centrally as estradiol falls and FSH rises. In people in their 40s and 50s, this redistribution can resemble a pattern associated with PCOS. Age and earlier menstrual history help with interpretation. FSH can sometimes contribute, although whether to measure it depends on the clinical circumstances. PCOS during perimenopause and menopause adds further complexity. With established PCOS, the history generally extends back into earlier reproductive years, even as symptoms persist or change. Source 1

Prolactinoma and androgen-producing tumors are uncommon possibilities that may also need consideration. Prolactin testing can contribute to an evaluation for prolactinoma, but an elevated value alone neither confirms it nor excludes PCOS. Rapid-onset virilization, pronounced androgen-related physical changes, together with markedly elevated total testosterone or DHEA-S, can suggest an ovarian or adrenal androgen-producing tumor. This warrants prompt specialist evaluation.

What a clinical assessment involves

A clinical assessment combines the Rotterdam criteria with hormone testing and an assessment of metabolism. Which tests are useful depends on symptoms and previous findings. The 2023 international PCOS guideline distinguishes between generally indicated assessments and those needed only in particular circumstances. Source 1

The timing of blood sampling can affect interpretation. Follicular-phase sampling, often on days 2 through 5 of the menstrual cycle, is mentioned for several markers. That is not a universal timing requirement for every test below.

The free androgen index, or FAI, is calculated from total testosterone and SHBG. It provides an indirect indication of biologically available androgen exposure and can contribute to assessing hyperandrogenism.
Sex hormone-binding globulin, or SHBG, is often lower when insulin resistance accompanies PCOS. This can increase the FAI and effective androgen exposure.
Total and free testosterone assess androgen levels. Mild elevations are common in PCOS. Markedly elevated values may prompt investigation for an androgen-producing tumor.
DHEA-S is a marker of adrenal androgens and can help distinguish an adrenal contribution from an ovarian source of androgen excess.
17-hydroxyprogesterone helps assess nonclassic congenital adrenal hyperplasia. Elevated results can lead to a confirmatory ACTH stimulation test. Morning follicular-phase sampling is generally used.
Fasting insulin and HOMA-IR are used to assess insulin resistance, which affects a substantial proportion of people with PCOS independently of BMI. However, the international guideline does not recommend clinically available insulin assays routinely. HOMA-IR is therefore not a universal required part of a PCOS assessment.
HbA1c provides an indication of average blood glucose over roughly three months and can identify impaired glucose regulation. In PCOS, the 75-g oral glucose tolerance test is most accurate regardless of BMI. When it cannot be performed, fasting glucose and/or HbA1c may be considered, with substantially lower accuracy.
A lipid profile contributes to cardiometabolic risk assessment because PCOS is associated with increased cardiovascular risk. Source 1 Source 2 Source 3 Source 4 Source 5 Source 6 Source 7

Laboratory results complement history and other findings; they do not diagnose PCOS on their own. Sex hormone levels vary across the menstrual cycle. The follicular phase is often used to aid interpretation of testosterone and SHBG. Fasting insulin is influenced by factors including whether the person has actually fasted and their preceding diet.

Reference ranges and clinical presentations can also vary among populations. Research on regional hormonal and metabolic differences illustrates why laboratory results need clinical interpretation. In adults, two of three diagnostic features must be present after other causes are excluded, and medical history remains essential to that assessment. Source 1

When a broader assessment makes sense

Weight gain centered on the abdomen is common and has many possible explanations. When other symptoms accompany it, a closer look at hormonal or metabolic factors can be useful. Clinicians, often in endocrinology or gynecology, assess the overall picture.

The following patterns warrant evaluation but do not establish a diagnosis:

From three years after the first menstrual period until perimenopause, cycles shorter than 21 days, longer than 35 days, or fewer than eight cycles per year. No additional six-month waiting period is required; different limits apply in the first years after menarche.
New or worsening hirsutism, androgen-pattern scalp hair loss, or severe persistent acne, particularly alongside central fat accumulation.
Difficulty conceiving after 12 months of regular unprotected intercourse, or after six months from age 35 onward. PCOS or type 2 diabetes in first-degree relatives is also relevant to assessment.

These timeframes do not mean that concerning or rapidly worsening symptoms should be left for six or 12 months before seeking care. Whether a threshold fits the situation depends on factors including age, life stage, and how symptoms develop.

A menstrual diary can make the appointment more useful. Record typical, shortest, and longest cycle lengths and the dates of the last three to six periods. Notes on where excess hair grows, the pattern of acne, and the type of hair loss add context. Previous laboratory results and a current medication list complete the picture. Depending on symptoms, referral to endocrinology or gynecology may be helpful.

Putting symptoms and findings together

Recording how symptoms change provides a useful basis for a clinical discussion. It helps identify which assessments are likely to clarify the diagnosis.

FAI, SHBG, fasting insulin, HbA1c, DHEA-S, and 17-hydroxyprogesterone can each contribute information about hormones or metabolism in the appropriate setting. None diagnoses PCOS by itself, and not every test is useful in every situation. The limitation discussed above applies to fasting insulin and HOMA-IR: the guideline does not recommend them for routine PCOS assessment. Source 1 Source 2 Source 3 Source 4 Source 5 Source 6

Carefully selected and professionally interpreted laboratory tests can provide useful information. Their value lies in that additional guidance; testing cannot promise a particular health outcome.

Frequently asked questions

Is “PCOS belly” real?

Many people with PCOS accumulate more fat around the abdomen. Hormonal and metabolic factors may influence fat distribution and visceral and ectopic fat stores. These relationships are discussed in abdominal-fat research, a guideline publication, and a study of ectopic fat stores. Source 1 Source 2 Source 3

“PCOS belly” is not a medical diagnosis, however. It mixes a feature some people have with the condition itself. An abdominal pattern of fat distribution does not demonstrate PCOS, and treating the two as equivalent can lead to misdiagnosis.

Can PCOS be diagnosed from body shape alone?

No. In adults, two of three features are required after other causes have been excluded: ovulatory dysfunction, hyperandrogenism, and polycystic ovarian morphology, assessed by ultrasound or alternatively AMH within the diagnostic algorithm. AMH is not a stand-alone diagnostic test. Adolescents have stricter criteria requiring both ovulatory dysfunction and hyperandrogenism; ultrasound and AMH are not recommended for this purpose. Body shape is not a criterion. Similar changes can occur with Cushing syndrome, hypothyroidism, nonclassic congenital adrenal hyperplasia, and perimenopause. Source 1

Which laboratory tests may be useful in PCOS?

Depending on the findings, assessment may include total testosterone, free testosterone or FAI and SHBG, DHEA-S when indicated, and 17-hydroxyprogesterone to investigate other causes. Metabolic assessment uses a lipid profile and appropriate glucose testing. The guideline favors the 75-g oral glucose tolerance test in PCOS. When that is not possible, fasting glucose or HbA1c are less accurate alternatives. Fasting insulin and HOMA-IR do not form a recommended routine test panel.

The choice of tests depends on clinical judgment. Medical history and the other diagnostic criteria are part of the assessment as well.

What do normal laboratory results mean if PCOS symptoms persist?

Normal results do not automatically exclude PCOS. Hormone levels vary across the cycle, and test timing can affect interpretation. A clinician can assess whether selected tests should be repeated at an appropriate time, whether ovarian ultrasound would help, or whether an endocrinology or gynecology referral is useful.

Ultrasound assesses the characteristic appearance of the ovaries. Describing it simply as a search for “ovarian cysts” is misleading. Repeating blood tests in a different cycle phase is likewise not useful for every marker and should be planned selectively.

What information helps with a PCOS assessment?

A menstrual diary covering cycle length, regularity, and the last three to six periods is useful, along with notes on increased hair growth, acne, and hair changes. Previous laboratory results and a current medication list also help put testing into the context of the Rotterdam criteria.

Could an apparent “PCOS belly” have another explanation?

Yes. Central abdominal fat accumulation has many possible explanations, including Cushing syndrome, hypothyroidism, nonclassic congenital adrenal hyperplasia, insulin resistance without PCOS, and redistribution of visceral fat during perimenopause. Depending on the findings, prolactinoma and androgen-producing tumors may also need consideration. Clinical assessment helps distinguish these possibilities from PCOS.

How often should laboratory tests be repeated in PCOS?

The interval depends on the test and previous findings, so it should be determined clinically. Borderline results may warrant repeat testing at a suitable time in the cycle or after lifestyle changes.

For glucose metabolism, the guideline recommends reassessment every one to three years, depending on additional diabetes risk factors. That is not a schedule for every hormone measurement. It does not support a blanket three-to-six-month interval or repeating all tests in another cycle phase. Source 1

Which biomarkers belong in a complete PCOS assessment?

Markers discussed here include FAI, SHBG, total and free testosterone, DHEA-S, 17-hydroxyprogesterone, fasting insulin and HOMA-IR, HbA1c, and a lipid profile. They can provide hormonal and metabolic information; which are needed depends on the clinical question. Fasting insulin and HOMA-IR are not routinely recommended, and the 75-g oral glucose tolerance test should be considered for glucose assessment. Source 1 Source 2 Source 3 Source 4

A complete PCOS evaluation also includes medical history and the necessary clinical examinations. The listed laboratory values alone cannot fully assess ovulation either.

References and sources

Teede HJ, Tay CT, Laven J, Dokras A, Moran LJ, Piltonen TT, Costello MF, Boivin J, M Redman L, A Boyle J, Norman RJ, Mousa A, Joham AE, International PCOS Network (2023). Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertility and sterility, 120(4), 767-793. https://doi.org/10.1016/j.fertnstert.2023.07.025
Teede HJ, Tay CT, Laven J, Dokras A, Moran LJ, Piltonen TT, Costello MF, Boivin J, Redman LM, Boyle JA, Norman RJ, Mousa A, Joham AE, International PCOS Network (2023). Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome†. Human reproduction (Oxford, England), 38(9), 1655-1679. https://doi.org/10.1093/humrep/dead156
Teede HJ, Mousa A, Tay CT, Costello MF, Brennan L, Norman RJ, Pena AS, Boyle JA, Joham A, Berry L, Moran L (2024). Summary of the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome: an Australian perspective. The Medical journal of Australia, 221(7), 389-395. https://doi.org/10.5694/mja2.52432
Peña AS, Witchel SF, Boivin J, Burgert TS, Ee C, Hoeger KM, Lujan ME, Mousa A, Oberfield S, Tay CT, Teede H (2025). International evidence-based recommendations for polycystic ovary syndrome in adolescents. BMC medicine, 23(1), 151. https://doi.org/10.1186/s12916-025-03901-w
Jena D, Choudhury AK, Mangaraj S, Singh M, Mohanty BK, Baliarsinha AK (2018). Study of Visceral and Subcutaneous Abdominal Fat Thickness and Its Correlation with Cardiometabolic Risk Factors and Hormonal Parameters in Polycystic Ovary Syndrome. Indian journal of endocrinology and metabolism, 22(3), 321-327. https://doi.org/10.4103/ijem.IJEM_646_17
de Melo Cavalcante RB, Leão, L. M. C. S. M., Tavares ABW, Lopes KG, Terra C, Salgado AA, Kraemer-Aguiar LG (2025). Visceral adipose tissue, epicardial fat, and hepatic steatosis in polycystic ovary syndrome: a study of ectopic fat stores and metabolic dysfunction. Endocrine, 87(2), 866-874. https://doi.org/10.1007/s12020-024-04077-8
Dumesic DA, Padmanabhan V, Abbott DH (2025). POLYCYSTIC OVARY SYNDROME: ORIGINS AND IMPLICATIONS: Polycystic ovary syndrome: an evolutionary metabolic adaptation. Reproduction (Cambridge, England), 169(4). https://doi.org/10.1530/REP-25-0021
Carbone L, Davis BA, Fei SS, White A, Nevonen KA, Takahashi D, Vinson A, True C, Roberts CT, Varlamov O (2019). Synergistic Effects of Hyperandrogenemia and Obesogenic Western-style Diet on Transcription and DNA Methylation in Visceral Adipose Tissue of Nonhuman Primates. Scientific reports, 9(1), 19232. https://doi.org/10.1038/s41598-019-55291-8
Levate G, Wang Y, McCredie R, Fenwick M, Rae MT, Duncan WC, Siemienowicz KJ (2025). Insights into the effects of sex and tissue location on the evolution of adipocyte dysfunction in an ovine model of polycystic ovary syndrome (PCOS). Molecular and cellular endocrinology, 595, 112416. https://doi.org/10.1016/j.mce.2024.112416
Tay CT, Mousa A, Vyas A, Pattuwage L, Tehrani FR, Teede H (2024). 2023 International Evidence-Based Polycystic Ovary Syndrome Guideline Update: Insights From a Systematic Review and Meta-Analysis on Elevated Clinical Cardiovascular Disease in Polycystic Ovary Syndrome. Journal of the American Heart Association, 13(16), e033572. https://doi.org/10.1161/JAHA.123.033572
Amiri M, Hatoum S, Hopkins D, Buyalos RP, Ezeh U, Pace LA, Bril F, Sheidaei A, Azziz R (2024). The Association Between Obesity and Polycystic Ovary Syndrome: An Epidemiologic Study of Observational Data. The Journal of clinical endocrinology and metabolism, 109(10), 2640-2657. https://doi.org/10.1210/clinem/dgae488
Shan C, Yu J, Zhu YC, Zhao J, Wang LH, Li YS, Lin SY, Liu W, Lu Q, Tao T (2025). Pancreatic Body and Hepatic Fat Content Predict Impaired Glucose Regulation in Women With Polycystic Ovary Syndrome. The Journal of clinical endocrinology and metabolism, 111(1), e247-e259. https://doi.org/10.1210/clinem/dgaf272
Papalou O, Victor VM, Diamanti-Kandarakis E (2016). Oxidative Stress in Polycystic Ovary Syndrome. Current pharmaceutical design, 22(18), 2709-22. https://doi.org/10.2174/1381612822666160216151852
Merhi Z, Kandaraki EA, Diamanti-Kandarakis E (2019). Implications and Future Perspectives of AGEs in PCOS Pathophysiology. Trends in endocrinology and metabolism: TEM, 30(3), 150-162. https://doi.org/10.1016/j.tem.2019.01.005
Joham AE, Teede HJ, Cassar S, Stepto NK, Strauss BJ, Harrison CL, Boyle J, de Courten B (2016). Vitamin D in polycystic ovary syndrome: Relationship to obesity and insulin resistance. Molecular nutrition & food research, 60(1), 110-8. https://doi.org/10.1002/mnfr.201500259
Wilson C, Chiang-Hanisko L, Kaleem S, Aljadani M, Mendonca J, Arshad S, Pirrone N, Follin T, Sacca L (2026). Lifestyle and Complementary Approaches to Polycystic Ovary Syndrome During Perimenopause and Menopause A Scoping Review. American journal of lifestyle medicine, 15598276261436778. https://doi.org/10.1177/15598276261436778
VanHise K, Chan JL, Wertheimer S, Handelsman RG, Clark E, Buttle R, Wang ET, Azziz R, Pisarska MD (2023). Regional Variation in Hormonal and Metabolic Parameters of White and Black Women With PCOS in the United States. The Journal of clinical endocrinology and metabolism, 108(3), 706-712. https://doi.org/10.1210/clinem/dgac515

PubMed links

Additional biomarker descriptions: These commercial information pages are not independent scientific evidence.